Preclinical Research

  • Preclinical Research
  • Eye-Opening Insights on Ophthalmic Drug Development


     

    Our Commitment to Better Vision
    and Eye Health

    With a deep understanding of the unique challenges presented by ocular drug development, Altasciences combines cutting-edge research, advanced technological platforms, and comprehensive regulatory expertise to support your program from lead candidate selection to market.

    Our end-to-end ophthalmic expertise includes:

        •   50 years of experience with all ophthalmic therapeutic indications—no study ever rejected for reasons of design, conduct, or data integrity;

        •   all ophthalmic routes of administration and specialized techniques;

        •   many different types of formulations, including nanoparticles and ocular implants;

        •   ocular studies performed in multiple species (rodent and non-rodent);

        •   more than 40 ophthalmology clinical trials conducted;

        •   on-site Diplomate, American College of Veterinary Ophthalmologists (DACVO);

        •   significant investment in specialized equipment like optical coherence tomography (OCT) and RetCam; and

        •   state-of-the-art bioanalytical instrumentation and assay platforms.

    Ready to dive deeper? Explore our full range of integrated CRO/CDMO ophthalmic drug development services and how they can accelerate your timeline by up to 40%.

    Do you have an ocular drug compound in your development pipeline?
    Speak with one of our experts about your study and let’s get you started!

    Related resources that may interest you:

    Webinar: Gene and Cell Therapy―Enhanced CNS and Ocular Delivery in NHPs
    Fact Sheet: Our Comprehensive Ophthalmic Drug Development Services
    Scientific Journal: The Complexities of Early Phase Ophthalmic Drug ​​​Development


     

    Unveiling the Layers of Nonclinical Dermal Studies


     

    In this issue of The Altascientist, we review the specific nonclinical requirements to move a dermal program forward to Phase I clinical trials and how to minimize inherent challenges―a case study using the minipig model is included.

     

    READ THE ISSUE

     

    Considerations for nonclinical dermal studies - Advancing to phase 1

     

    Altasciences has decades of experience supporting dermal drug development programs, from initial efficacy to clinical proof of concept. We boast one of North America's largest herds of miniature swine, including the most popular breeds of minipigs for dermal studies.

     

    Speak with one of our experts today and let's get your program underway.

     

     

    ​​Related resources that may interest you:

        •   Webpage: Preclinical Research Services
        •   eBook: Scratching the Surface of Nonclinical Dermal Testing
        •   Webinar: Downsized Miniature Swine―A New Spin on the Oldest Model


     

    Looking to Reshore Your Drug Development Program?


     

    Addressing the Biosecurity Act—A Network of Sites That Works for You

    As geopolitical uncertainties still linger following the report of the Biosecurity Act, numerous pharmaceutical and biotech firms are prioritizing stability by reshoring their R&D outsourcing. Altasciences, with our nine facilities spread across the United States and Canada, is ideally positioned to meet your requirements.

    Our network includes:

        •   preclinical facilities in Seattle, Sacramento, Columbia (MO), and Scranton;
        •   clinical units in Los Angeles, Kansas City, and Montréal;
        •   bioanalytical laboratories in Seattle, Columbia (MO), and Laval; and​​​​​​
        •   manufacturing facility in Philadelphia.

    Discover more about each of our strategically located sites and how they can support your drug development programs.

     

    Related resources that may interest you:
        •   Webpage: Altasciences’ Early-Phase Drug Development Services
        •   eBook: Regulatory Comparisons for Starting FIH Clinical Trials
        •   eBook: Advantages of Conducting Clinical Trials in Canada


     

    Must-Read Scientific Posters Presented by Our Preclinical Experts

     

    LATEST SCIENTIFIC POSTERS PRESENTED BY OUR PRECLINICAL EXPERTS

    Hot off the press! We're excited to showcase our latest collection of 11 new scientific posters, unveiled at the 
    63rd Annual Society of Toxicology (SOT) Meeting.

    Dive deep into a series of preclinical findings:

    •    Sinclair Nanopig™: From Multi-Omics Characterization to Pharmacology and Toxicology Validation: Underline Drug Metabolism and Immune System Presented by Yafei Chen, Senior Research Fellow, Pathology Services

    •    Cross-Comparison of Immunophenotyping Assay Performance in Naïve Filipino, Mauritian, and Cambodian Nonhuman Primates Presented by Derek Hanson, Principal Scientist

    •    Historical Background Data in Juvenile Cynomolgus Monkeys: Comparative Immunotoxicology and Pathology of Different Origins Presented by Narine Lalayeva, Associate Director, Safety Assessment

    •    Cross-Comparison of Biomarker Assay Performance in Naïve Philippines, Cambodian, and Mauritius, and Non-Naïve Mauritius Cynomolgus Macaque Nonhuman Primates Presented by Catherine Schilffarth, Associate Director, Operations, Laboratory Sciences

    •    28-Day Intranasal Toxicity Study of MMS019 in Sprague Dawley Rats and Dogs Presented by Kyle Klepner, Senior Scientist, Study Director, Safety Assessment

    •    Tissue Biopsy Collections in Nonhuman Primates During Toxicology Studies: A Comparison of Findings with Animals Not Sampled Presented by Narine Lalayeva, Associate Director, Safety Assessment

    •    Incidence of Neutralizing Adeno-Associated Viral Antibody Subtypes in Cynomolgus Monkeys of Cambodian, Mauritius, and Philippines Origins Presented by Julie Forget, Senior Director, Safety Assessment

    •    Development of a Novel Early Intervention Stabilization for Abdominal Aortic Aneurysms Presented by Timothy J. Madsen, Associate Scientific Director, General Toxicology

    •    Development of a Canine Prostatectomy Model for Use in the Toxicity Evaluation of Oncology Drugs  Presented by Ahmed Abdalla, Associate Scientist, Study Director

    •    Comparison of Safety Pharmacology End Points Used on Toxicology Studies Across Differing Cynomolgus Monkey Origins Presented by Jean-Christophe Queudot, Associate Director, Safety Pharmacology 

    •    Clinical Pathology Reference Data for the Philippine Cynomolgus Monkey for Preclinical Toxicology Studies Presented by Dr. Johanna Rigas, Veterinary Clinical Pathologist

    Questions? Speak with one of our experts about your small or large molecule preclinical projects. We can get your study started within the next two months!
     
     

     

     

     

    Clinical Pathology Reference Data for the Philippine Cynomolgus Monkey for Preclinical Toxicology Studies

    Comparison of Safety Pharmacology End Points Used on Toxicology Studies Across Differing Cynomolgus Monkey Origins

    Cross-Comparison of Biomarker Assay Performance in Nonhuman Primates

    Cross-Comparison of Immunophenotyping Assay Performance in Nonhuman Primates

    Subscribe to Preclinical Research